Jasper Therapeutics, Inc. (JSPR) Income Statement
JSPR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJSPR revenue and net income
JSPR profit margins
JSPR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JSPR quarterly EPS vs estimates
Jasper Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.06).
JSPR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $13.5M | $6.2M | $0 | $0 |
| Cost of revenue | $1.1M | $1.4M | $1.1M | $1.3M | $566,000 | $21,000 | — |
| Gross profit | −$1.1M | −$1.4M | −$1.1M | −$1.3M | −$566,000 | −$21,000 | — |
| Research & development | $60.5M | $55.8M | $51.8M | $34.6M | $25.4M | $15.9M | $3.6M |
| Sales, general & admin | $18.9M | $20.4M | $18.2M | $16.6M | $11.4M | $4.8M | $1.1M |
| Total operating expenses | $79.5M | $76.2M | $68.9M | $51.2M | $36.8M | $20.7M | $4.7M |
| Operating income | −$80.5M | −$76.2M | −$68.9M | −$51.2M | −$36.8M | −$20.7M | −$4.7M |
| Interest income | $1.7M | $5.1M | $5.2M | $701,000 | — | — | — |
| Interest expense | — | — | — | $13.5M | $6.2M | $11.0M | $0 |
| Income before taxes | −$75.8M | −$71.3M | −$64.5M | −$37.7M | −$30.6M | −$31.7M | −$5.0M |
| Income taxes | — | −$1.5M | −$1.6M | −$13.5M | −$1.1M | −$38,451 | −$277 |
| Net income | −$75.8M | −$71.3M | −$64.5M | −$37.7M | −$30.6M | −$31.7M | −$5.0M |
| EBITDA | −$74.7M | −$69.9M | −$63.4M | −$36.7M | −$30.3M | −$31.9M | −$277,000 |
| EPS (diluted) | −$4.82 | −$4.86 | −$6.11 | −$9.55 | −$4.33 | $0.06 | $0.00 |
| Gross margin | — | — | — | −9.7% | −9.1% | — | — |
| Operating margin | — | — | — | −378.9% | −594.5% | — | — |
| Net margin | — | — | — | −278.9% | −494.5% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M | $0 | $0 | $0 | $2.1M | $0 |
| Cost of revenue | — | $21,000 | $290,000 | — | $258,000 | $279,000 | $587,000 | $541,000 | $299,000 | $288,000 | $82,000 | $276,000 |
| Gross profit | — | −$21,000 | −$290,000 | — | −$258,000 | −$279,000 | $587,000 | −$541,000 | −$299,000 | −$288,000 | −$82,000 | −$276,000 |
| Research & development | $5.1M | $5.8M | $11.4M | $14.4M | $21.2M | $16.2M | $19.8M | $14.5M | $11.3M | $10.3M | $13.8M | $14.8M |
| Sales, general & admin | $4.1M | $5.1M | $4.5M | $4.8M | $5.9M | $5.6M | $5.8M | $5.4M | $4.7M | $4.8M | $4.2M | $4.5M |
| Total operating expenses | $9.2M | $10.9M | $15.8M | $19.2M | $27.1M | $21.8M | $25.3M | $19.9M | $16.0M | $14.8M | $17.7M | $19.4M |
| Operating income | −$9.2M | −$11.0M | −$15.8M | −$19.2M | −$27.1M | −$21.8M | −$25.3M | −$19.9M | −$16.0M | −$15.1M | −$17.7M | −$19.4M |
| Interest income | $82,000 | $164,000 | $338,000 | $342,000 | $437,000 | $624,000 | $938,000 | $1.3M | $1.4M | $1.4M | $1.2M | $1.4M |
| Interest expense | — | — | — | — | — | — | $5.1M | — | — | — | $313,000 | — |
| Income before taxes | −$2.8M | −$1.2M | −$9.1M | −$18.7M | −$26.7M | −$21.2M | −$24.3M | −$18.6M | −$14.6M | −$13.7M | −$16.6M | −$17.5M |
| Income taxes | — | — | — | — | — | — | $54,276 | — | −$299,000 | $244,724 | $1.9M | −$1.7M |
| Net income | −$2.8M | −$1.2M | −$9.1M | −$18.7M | −$26.7M | −$21.2M | −$24.3M | −$18.6M | −$14.6M | −$13.7M | −$16.6M | −$17.5M |
| EBITDA | −$2.7M | −$1.2M | −$8.8M | −$18.5M | −$26.5M | −$21.0M | −$24.1M | −$18.1M | −$14.3M | −$13.4M | −$16.3M | −$17.3M |
| EPS (diluted) | −$0.24 | −$0.38 | −$0.54 | −$1.13 | −$1.74 | −$1.41 | −$1.62 | −$1.24 | −$0.97 | −$1.03 | −$1.50 | −$1.63 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | −4.0% | — |
| Operating margin | — | — | — | — | — | — | −2,153.7% | — | — | — | −863.8% | — |
| Net margin | — | — | — | — | — | — | −2,071.6% | — | — | — | −808.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JSPR's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JSPR financial results
Jasper Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $75.8 million. Diluted earnings per share came to −$4.82.
See the JSPR stock overview for the latest quote and news, or the JSPR chart for price history and technical indicators.
JSPR income statement FAQ
Does Jasper Therapeutics have revenue?
Jasper Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Jasper Therapeutics profitable?
No. Jasper Therapeutics reported a net loss of $75.8 million in fiscal 2025.
How much does Jasper Therapeutics spend on research and development?
Jasper Therapeutics spent $60.5 million on research and development in fiscal 2025.
What are Jasper Therapeutics's earnings per share?
Jasper Therapeutics earned $-4.82 per diluted share in fiscal 2025, compared with $-4.86 a year earlier.
When will Jasper Therapeutics report its next earnings?
Jasper Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Jasper Therapeutics's fiscal year end?
Jasper Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.